Latest filing published 24 Feb 2026 for Halozyme Therapeutics, INC..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Nicole LaBrosse is a declared insider of Halozyme Therapeutics, Inc. (finance chief), with filings sourced from SEC (Form 4). We count 62 filings; the first trade dates from 10 February 2022 and the latest from 23 February 2026.
The open-market record consists of 12 sales worth €3.5M, with no purchase. Other entries cover 21 share grants and 29 option exercises.
The newest entry dates from 24 February 2026: an option exercise, in Halozyme Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations